Investigational Drug Information for Varespladib
What is the development status for investigational drug Varespladib?
Varespladib is an investigational drug.
There have been 11 clinical trials for Varespladib.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2010.
The most common disease conditions in clinical trials are Syndrome, Snake Bites, and Anemia, Sickle Cell. The leading clinical trial sponsors are Anthera Pharmaceuticals, Ophirex, Inc., and Premier Research International LLC.
Summary for Varespladib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 281 |
| WIPO Patent Applications | 100 |
| Japanese Patent Applications | 26 |
| Clinical Trial Progress | Phase 2 (2010-05-01) |
| Vendors | 58 |
Recent Clinical Trials for Varespladib
| Title | Sponsor | Phase |
|---|---|---|
| Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO) | Ophirex, Inc. | Phase 2 |
| Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite | Premier Research International LLC | Phase 2 |
| Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite | Ophirex, Inc. | Phase 2 |
Clinical Trial Summary for Varespladib
Top disease conditions for Varespladib
Top clinical trial sponsors for Varespladib
US Patents for Varespladib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Varespladib Development Update and Market Projection
Varespladib is an investigational oral small-molecule inhibitor of secretory phospholipase A2 enzymes. Its commercial development has shifted from cardiovascular disease to snakebite envenoming, where the drug is being developed by Ophirex as a potential broad-spectrum, field-administered treatment. Varespladib has no FDA approval, no Orange Book listing, and no established commercial revenue base as of June 2024. Its market value depends on successful clinical development, regulatory acceptance of an emergency-use model, manufacturing scale-up, and procurement by governments and humanitarian organizations.
The most credible commercial opportunity is a public-health market for snakebite treatment rather than a conventional retail prescription market. A reasonable long-term revenue range is approximately $50 million to $300 million annually, with upside above that level if the product receives broad geographic approval, is adopted in national treatment protocols, and obtains premium pricing for an emergency oral formulation. These figures are scenario estimates, not reported company guidance.
What is varespladib and how does it work?
Varespladib, also identified as LY315920, is an inhibitor of secretory phospholipase A2, or sPLA2. Varespladib methyl, identified as LY333013, is an oral prodrug or formulation historically evaluated to improve administration and exposure.
sPLA2 enzymes are present in the venoms of many medically important snakes. They contribute to tissue destruction, neurotoxicity, inflammation, hemolysis, coagulopathy, and muscle injury. Varespladib has broad inhibitory activity against several venom sPLA2 isoforms, creating a potential mechanism for use across multiple snake species rather than against only one regional venom.
The development thesis is that early oral administration could slow systemic venom injury before a patient reaches a hospital. The drug would not necessarily replace antivenom. It could be used as an initial intervention, followed by antivenom and supportive care when available.
What is the current development status of varespladib?
Varespladib remains an investigational drug. Ophirex is the principal publicly identified developer for the snakebite indication. The company has evaluated oral varespladib in preclinical venom models and human clinical studies directed at snakebite envenoming.
Development milestones
| Period | Development event |
|---|---|
| 2000s | Varespladib was developed for cardiovascular and inflammatory indications. |
| 2010-2012 | Anthera Pharmaceuticals evaluated varespladib in acute coronary syndrome, including the Phase 3 VISTA-16 program. |
| 2012 | The VISTA-16 trial did not meet its primary efficacy objective in acute coronary syndrome. |
| 2016-2019 | Academic and translational research supported sPLA2 inhibition as a potential treatment for snakebite envenoming. |
| 2019 onward | Ophirex advanced oral varespladib for snakebite, supported by government and nonprofit funding. |
| 2021-2024 | Clinical development and regulatory planning continued, including work relevant to endemic regions and field deployment. |
The failed cardiovascular program does not establish failure in snakebite. The indications have different disease biology, treatment timing, endpoints, and commercial requirements. The prior human safety database may reduce some development risk, but it does not remove the need to demonstrate benefit in envenomed patients.
What clinical evidence supports varespladib for snakebite?
Preclinical studies have reported inhibition of venom-induced pathology in animal and ex vivo models. These studies have included venoms from several snake families and have supported the concept of a broad-spectrum sPLA2 inhibitor.[1]
Human development has focused on safety, pharmacokinetics, feasibility, and clinical outcomes in snakebite patients. The central efficacy question is whether early varespladib administration reduces mortality, neurotoxicity, coagulopathy, tissue injury, or the need for intensive care when given before or alongside antivenom.
The principal clinical risks are:
- Treatment may be administered after irreversible venom injury has occurred.
- sPLA2 inhibition may not neutralize venom components driven by other toxin classes.
- Clinical outcomes may vary materially by snake species and geography.
- A trial may need to account for antivenom access, transport time, and hospital quality.
- A product that delays antivenom administration could create a safety concern.
The most commercially useful label would likely cover early treatment of suspected snakebite envenoming, potentially with subsequent referral and standard hospital treatment.
When could varespladib reach the market?
No public FDA approval date has been established. The path to market could require a late-stage efficacy trial, manufacturing validation, regulatory review, and post-approval evidence.
Potential regulatory pathways
| Regulatory route | Relevance to varespladib |
|---|---|
| Traditional approval | Requires clinical evidence demonstrating safety and efficacy in the target population. |
| Orphan-drug pathway | Could apply to specific rare snakebite populations or defined geographic indications, but snakebite globally affects a large population. |
| Priority review | Possible if the product addresses a serious condition with limited treatment options and provides meaningful benefit. |
| Animal Rule | Potentially relevant if human efficacy trials are difficult or unethical, provided the mechanism and animal models meet FDA requirements. |
| Emergency or government procurement | Could support deployment in high-risk regions but would not substitute for marketing authorization. |
The Animal Rule is commercially important because snakebite trials are difficult to standardize. Snake species, venom dose, time to treatment, antivenom availability, and clinical endpoints differ across countries. A regulatory strategy based partly on validated animal models could reduce trial complexity, but the pathway remains demanding.
A commercial launch before 2027 would require rapid completion of pivotal development and regulatory review. A more conservative launch window is 2027-2029, assuming positive late-stage data and adequate funding.
What is the FDA status and Orange Book status of varespladib?
Varespladib is not an FDA-approved drug. It does not have an FDA-approved indication for snakebite, acute coronary syndrome, or any other disease.
Because there is no approved varespladib product, there is no relevant Orange Book reference product and no FDA-listed varespladib exclusivity period. The drug therefore has no current Hatch-Waxman generic-entry framework comparable to an approved branded medicine.
FDA and exclusivity position
| Item | Status |
|---|---|
| FDA approval | None identified |
| Approved active ingredient | None in the U.S. |
| Orange Book listing | None |
| U.S. generic competition | No approved generic product |
| New chemical entity exclusivity | Not currently applicable |
| Pediatric exclusivity | None identified |
| Orphan exclusivity | No U.S. approval-based orphan exclusivity identified |
| Regulatory exclusivity start date | None |
| Commercial launch date | Not established |
If approved, protection could arise from new clinical-use patents, formulation patents, orphan exclusivity, pediatric exclusivity, and regulatory data exclusivity. The strength of that protection would depend on the final product, indication, and patent filings.
What patents protect varespladib?
The original composition-of-matter and cardiovascular development patents for varespladib are old relative to the current snakebite program. Core small-molecule patent protection is therefore unlikely to provide a long period of new-product exclusivity.
The more relevant future protection would involve:
- Oral formulations optimized for rapid absorption.
- Stable tablets suitable for high-temperature and high-humidity storage.
- Combination treatment with antivenom.
- Treatment of snakebite envenoming using defined dosing schedules.
- Use before hospital arrival or before antivenom administration.
- Manufacturing processes and solid-state forms.
- Pediatric and weight-based dosing.
- Geographic or species-specific treatment protocols.
Method-of-use claims can be commercially useful even when composition patents have expired. Their practical value depends on claim breadth, enablement, prior art, prosecution history, and whether competitors can design around the patented dosing or treatment sequence.
No current, verified U.S. Orange Book-listed varespladib patent estate exists because the drug has not been approved. The public commercial position is therefore better described as development-stage intellectual property rather than an established branded-drug patent moat.
How strong is the varespladib patent estate?
The patent position appears mixed.
Strengths
Varespladib has a known mechanism, an existing safety history, and a potential new-use field with substantial unmet need. New clinical-use patents could protect a defined snakebite indication if the claims are supported by clinical or translational evidence. A product-specific formulation could create a second layer of protection.
Weaknesses
The underlying compound is not new. Earlier disclosures, prior clinical studies, and broad sPLA2 literature may limit claim scope. A competitor could challenge patents based on obviousness, lack of written description, enablement, or anticipation. If varespladib is marketed as the same active ingredient in a conventional oral tablet, formulation claims may have limited scope.
The strongest defensible position would combine regulatory exclusivity with narrowly tailored method-of-use claims and manufacturing know-how.
What market is available for varespladib?
The addressable market is concentrated in countries where snakebite incidence, mortality, and transport delays are high. The World Health Organization estimates that snakebite causes millions of bites and tens of thousands of deaths each year, with the greatest burden in Africa, Asia, and parts of Latin America.[2]
The product could be sold through four channels:
- Government procurement and national health systems.
- Humanitarian and nonprofit procurement.
- Hospital and emergency-care channels.
- Private purchase in agricultural, rural, and occupational markets.
The highest-volume markets may not support high private-pay pricing. A sustainable commercial model may require donor funding, advance-purchase commitments, tiered pricing, or government contracts.
Market scenario for 2030
| Scenario | Annual treated patients | Net price per treatment course | Estimated annual revenue |
|---|---|---|---|
| Low adoption | 250,000 | $100 | $25 million |
| Base case | 750,000 | $200 | $150 million |
| High adoption | 1.5 million | $300 | $450 million |
These scenarios assume one treatment course per patient and exclude revenue from government stockpiling, combination products, or expanded indications. The base-case range is more commercially realistic than the high-adoption scenario because distribution, diagnosis, financing, and clinician training will constrain uptake.
What companies are challenging or competing with varespladib?
No approved generic competitor currently challenges varespladib in the U.S. The relevant competitive set is broader than direct small-molecule competition.
Competitive products and approaches
| Competitor or approach | Competitive role |
|---|---|
| Polyvalent antivenom | Current standard of care; directly competes for treatment budgets and clinical protocol position. |
| Monoclonal antibody antivenoms | Potential future alternatives with improved specificity and manufacturing consistency. |
| Caprylic-acid or small-molecule toxin inhibitors | May target venom components through different mechanisms. |
| Traditional antiserum manufacturers | Established procurement relationships and distribution infrastructure. |
| Regional antivenom producers | Compete on price, species coverage, and local regulatory access. |
| Supportive hospital care | Remains necessary even if varespladib is approved. |
Varespladib’s commercial differentiation is oral administration and potential broad venom coverage. Its competitive disadvantage is that it may not neutralize all venom toxins and may need to be paired with antivenom.
What generic-entry risks exist?
Before approval, generic entry is not the principal risk. The more immediate risks are clinical failure, regulatory delay, financing constraints, and weak procurement adoption.
After approval, generic risks would depend on the patent and exclusivity package. A generic manufacturer could potentially enter after expiration of valid method-of-use, formulation, and regulatory protections. Because the active ingredient is old, an abbreviated application could become attractive if the approved product uses a conventional dosage form and the approved labeling is narrow.
A follow-on product could also seek a different label that avoids patented snakebite-use claims. This makes regulatory exclusivity and supply-chain advantages important parts of the commercial strategy.
What litigation and settlement agreements affect varespladib?
No major current U.S. patent litigation or Paragraph IV dispute involving an approved varespladib reference product has been publicly established. There is no Orange Book listing that would generate a standard Hatch-Waxman litigation pathway.
The historic cardiovascular development program involved corporate and clinical setbacks, including the failure of the VISTA-16 trial. Those events affected the original commercial program but do not create a current generic litigation framework for the snakebite indication.
No material public settlement agreement governing generic entry into a future approved varespladib snakebite product has been identified.
What licensing deals support varespladib development?
The current development model has relied on nonprofit, government, academic, and commercial collaboration. Ophirex has received support associated with U.S. government biodefense and global-health initiatives, including funding connected to the Biomedical Advanced Research and Development Authority and other public-sector programs.[3]
Earlier rights and development work were associated with Anthera Pharmaceuticals and the compound's cardiovascular program. The present value of those historical rights is distinct from the future value of snakebite-specific patents, regulatory approvals, manufacturing rights, and regional licenses.
A licensing transaction would likely be structured around one or more of the following:
- Geographic rights for Africa, India, Southeast Asia, or Latin America.
- Government procurement rights.
- Co-development funding.
- Manufacturing and distribution rights.
- Combination therapy with antivenom.
- Veterinary or emergency-medicine applications.
How does varespladib compare with antivenom?
| Attribute | Varespladib | Antivenom |
|---|---|---|
| Administration | Oral potential | Usually intravenous or intramuscular |
| Timing | Could be given before hospital arrival | Usually administered in a medical setting |
| Coverage | Potentially broad across sPLA2-containing venoms | Often species or region specific |
| Mechanism | Inhibits a venom enzyme class | Antibodies neutralize venom components |
| Manufacturing | Small-molecule chemical synthesis | Biological production and purification |
| Cold-chain burden | Potentially lower | Often significant |
| Replacement for antivenom | Unlikely in initial use | Current standard treatment |
| Commercial opportunity | Field treatment and adjunctive use | Established hospital procurement |
The likely commercial position is adjunctive treatment, not complete replacement. This distinction affects pricing, clinical trial design, and payer adoption.
What is the revenue exposure and investment outlook?
There is no approved-product revenue to protect. Commercial exposure is therefore binary and development-driven. A positive Phase 3 program could create a differentiated public-health asset with global licensing potential. A negative efficacy outcome would sharply reduce the value of the program because the core compound is old and alternative indications have already failed to generate a commercial product.
The investment case depends on five variables:
- Demonstrated reduction in clinically meaningful snakebite outcomes.
- A regulatory pathway that accepts heterogeneous global clinical data.
- A stable oral formulation suitable for tropical field conditions.
- Government or donor procurement commitments.
- Patent and exclusivity protection extending beyond approval.
The most likely commercial model is a mixed public-private market rather than a high-margin specialty-pharmaceutical launch.
Key Takeaways
- Varespladib is an investigational oral sPLA2 inhibitor with no FDA approval.
- Ophirex is the principal developer associated with the snakebite program.
- The cardiovascular program failed in acute coronary syndrome, but that result does not resolve the snakebite indication.
- There is no Orange Book listing, approved generic, or current Paragraph IV litigation framework.
- Core compound protection is old; future value depends on method-of-use, formulation, manufacturing, and regulatory exclusivity.
- Antivenom remains the primary competitive and clinical comparator.
- A reasonable base-case annual revenue scenario is approximately $150 million by 2030, subject to successful approval and procurement adoption.
- The earliest plausible commercial launch window is 2027-2029 under a successful development path.
FAQs
Is varespladib approved for snakebite?
No. Varespladib has not received FDA approval for snakebite envenoming or another commercial indication.
Can varespladib replace antivenom?
The current development rationale supports use as an early intervention or adjunct. It is not established as a complete replacement for antivenom.
Who owns varespladib?
Ownership and development rights have changed across the compound's history. Anthera Pharmaceuticals was associated with the cardiovascular program, while Ophirex has led the publicly disclosed snakebite development program.
Does varespladib have orphan-drug exclusivity?
No approved varespladib product with U.S. orphan exclusivity has been identified. Any future orphan designation or exclusivity would depend on the approved indication and FDA action.
What is the biggest commercial risk for varespladib?
The largest risk is failure to demonstrate clinically meaningful benefit in snakebite patients across diverse venom types and treatment settings. Procurement affordability and distribution capacity are the main post-approval market risks.
References
-
Lewin, M. R., et al. (2016). Varespladib, a phospholipase A2 inhibitor, reduces the toxicity of snake venoms in preclinical models. Toxins, 8(9), 248.
-
World Health Organization. (2023). Snakebite envenoming. https://www.who.int/news-room/fact-sheets/detail/snakebite-envenoming
-
U.S. Biomedical Advanced Research and Development Authority. (2021). BARDA medical countermeasure development and snakebite envenoming program materials. U.S. Department of Health and Human Services.
-
Anthera Pharmaceuticals, Inc. (2012). VISTA-16 clinical trial disclosures and corporate reports.
-
ClinicalTrials.gov. (2024). Studies evaluating varespladib for snakebite envenoming. U.S. National Library of Medicine.
More… ↓
